Anlotinib

Generic Name: Anlotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₂FN_₃O_₃

CAS Number: 1058156-90-3

Unique Ingredient Identifier: GKF8S4C432

Background: Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication: 用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Phase 2

Conditions: Metastatic Triple-Negative Breast Cancer

Interventions: Drug: Anlotinib
Drug: Capecitabine

First Posted Date: 2021-10-22

Last Posted Date: 2022-01-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 35

Registration Number: NCT05089643

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

Phase 2

Conditions: MGMT-Unmethylated Glioblastoma

Interventions: Drug: Anlotinib
Drug: AK105
Radiation: Radiotherapy

First Posted Date: 2021-09-05

Last Posted Date: 2021-09-05

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 28

Registration Number: NCT05033587

Locations: 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Phase 2

Not yet recruiting

Conditions: Carboplatin
Anlotinib
Urothelial Carcinoma
Urogenital Neoplasms
Cisplatin
Gemcitabine
Antineoplastic Agents

First Posted Date: 2021-09-01

Last Posted Date: 2021-09-01

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 53

Registration Number: NCT05030077

Locations: 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, China

TAS-102 and Anlotinib in ≥3 Lines mGC

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: TAS 102
Drug: Anlotinib

First Posted Date: 2021-08-31

Last Posted Date: 2024-02-12

Lead Sponsor: Zhejiang University

Target Recruit Count: 45

Registration Number: NCT05029102

Locations: 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer

Phase 2

Recruiting

Conditions: Gynecological Cancer

Interventions: Drug: Penpulimab
Drug: Anlotinib

First Posted Date: 2021-08-31

Last Posted Date: 2023-12-27

Lead Sponsor: Sichuan Cancer Hospital and Research Institute

Target Recruit Count: 86

Registration Number: NCT05028504

Locations: 🇨🇳
Shaanxi Provincial Cancer Hospital, Xi'an, Shanxi, China
🇨🇳
Sicchuan cancer hospital, Chengdu, Sichuan, China
🇨🇳
The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Hefei, China

and more 3 locations

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

Phase 1

Recruiting

Conditions: NSCLC

Interventions: Drug: Anlotinib
Drug: Toripalimab
Drug: SBRT 7Gy✖️5 QD

First Posted Date: 2021-08-25

Last Posted Date: 2023-07-06

Lead Sponsor: Hubei Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05021328

Locations: 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Phase 2

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Anlotinib

First Posted Date: 2021-08-11

Last Posted Date: 2021-08-11

Lead Sponsor: Shi Yuankai

Target Recruit Count: 20

Registration Number: NCT04999800

Locations: 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Phase 2

Conditions: Melanoma

Interventions: Drug: Camrelizumab
Drug: Anlotinib
Drug: nab-Paclitaxel

First Posted Date: 2021-07-28

Last Posted Date: 2021-08-03

Lead Sponsor: Di Wu

Target Recruit Count: 66

Registration Number: NCT04979585

Locations: 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer
Brain Metastases

Interventions: Drug: Anlotinib

First Posted Date: 2021-07-27

Last Posted Date: 2021-07-27

Lead Sponsor: Li-kun Chen

Target Recruit Count: 54

Registration Number: NCT04978753

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Anlotinib

First Posted Date: 2021-07-23

Last Posted Date: 2021-07-27

Lead Sponsor: Anqin Zhang

Target Recruit Count: 30

Registration Number: NCT04975451

Locations: 🇨🇳
Guangdong Women and Children Hospital, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy